Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:39 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer
NCT03979508 · Mayo Clinic · PHASE2 · terminated · last registry update 2026-11-02 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The primary biomarker (CD8/FOXP3) was rarely observed to be \< 1.6 in residual tumors examined in first stage of study.” | – | Registry record, Mayo Clinic |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CDK4 in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-27Also stopped (terminated): Pfizer, ARV-471 + Ribociclib (NCT05573555)
- 2026-10-26Phase 3 first posted: Jiangsu HengRui Medicine Co., Ltd., HRS-6209 + Letrozole + Dalpciclib/Palbociclib + Letrozole/Anastrozole (NCT07894328)
- 2026-10-14Also stopped (terminated): UNICANCER, Alpelisib + Ribociclib (NCT05625087)
- 2026-09-29Results posted on the registry: Arvinas Estrogen Receptor, Inc., Vepdegestrant + Vepdegestrant (NCT04072952)
- 2026-09-24Results posted on the registry: Tvardi Therapeutics, Incorporated, TTI-101 + Palbociclib (NCT05384119)
- 2026-09-24Also stopped (terminated): Tvardi Therapeutics, Incorporated, TTI-101 + Palbociclib (NCT05384119)
- 2026-09-04Results posted on the registry: University of Utah, Ribociclib + Belinostat (NCT04315233)
- 2026-09-04Also stopped (terminated): University of Utah, Ribociclib + Belinostat (NCT04315233)
- 2026-09-03Phase 3 first posted: SWOG Cancer Research Network, NSAI + CDK4/6i + NSAI + CDK4/6i + Capivasertib (NCT07802626)
- 2026-07-21Phase 3 first posted: UNICANCER, a drug against CDK4 (NCT07717450)
- 2026-07-10Results posted on the registry: Novartis Pharmaceuticals, Ribociclib + Letrozole (NCT03439046)
- 2026-07-10Also stopped (terminated): Novartis Pharmaceuticals, Ribociclib + Letrozole (NCT03439046)
- 2026-07-08Results posted on the registry: Novartis Pharmaceuticals, Ribociclib Placebo + Ribociclib (NCT03671330)
- 2026-07-06Phase 3 first posted: Daiichi Sankyo, Trastuzumab deruxtecan + Trastuzumab (NCT07683754)
- 2026-07-02Results posted on the registry: Dana-Farber Cancer Institute, Abemaciclib + Tamoxifen (NCT06001762)
- 2026-06-25Also stopped (terminated): SOLTI Breast Cancer Research Group, Ribociclib + Letrozole OR Fulvestrant + Palbociclib + Letrozole OR Fulvestrant (NCT05207709)
- 2026-06-15Phase 3 first posted: AstraZeneca, Camizestrant + Ribociclib (NCT07647328)
- 2026-04-15Also stopped (withdrawn): Centre Antoine Lacassagne, Ribociclib Oral Tablet (NCT05664893)
- 2026-03-31Also stopped (terminated): Criterium, Inc., Abemaciclib + Elacestrant (NCT04791384)
- 2026-03-25Phase 3 first posted: BeOne Medicines, BGB-43395 + Letrozole (NCT07492641)
- 2026-03-12Results posted on the registry: Spanish Breast Cancer Research Group, Doxorubicin + Cyclophosphamide (NCT04293393)
- 2026-03-11Results posted on the registry: Qamar Khan, Letrozole + Ribociclib (NCT02712723)
- 2026-02-24Results posted on the registry: City of Hope Medical Center, Fulvestrant + Letrozole (NCT02778685)
- 2026-02-20Also stopped (terminated): Dana-Farber Cancer Institute, Abemaciclib (NCT03130439)
- 2026-02-12Results posted on the registry: Alliance Foundation Trials, LLC., palbociclib + trastuzumab (NCT02947685)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision